申聯生物(688098.SH)選聘高豔春為公司總經理
格隆匯12月22日丨申聯生物(688098.SH)公佈,公司於近日收到公司董事長聶東昇先生遞交的書面辭職報告,辭去公司總經理一職。聶東昇先生自2006年9月以來,一直擔任公司董事長,2011年12月至今一直兼任公司研發中心主任一職,2018年9月28日開始兼任公司董事長、總經理、研發中心主任職務。
為了進一步加強公司管理團隊建設,提高公司管理水平和經營業績,增強公司競爭實力,加快公司發展,聶東昇先生決定辭去公司總經理職務,並提名高豔春女士擔任公司總經理。董事會經研究,同意聶東昇先生辭去公司總經理職務。聶東昇先生仍擔任公司董事長(法定代表人),繼續兼任公司研發中心主一職。
經聶東昇董事長提名,第二屆提名委員會第一次會議審查,第二屆董事會第十次會議審議通過了《關於選聘高豔春為公司總經理的議案》、《關於選聘高旭為公司副總經理的議案》、《關於選聘張震為公司技術總監的議案》等三個議案。
此外,公司技術總監、核心技術人員陳智英女士因個人原因辭去技術總監職務。離職後,陳智英女士不再擔任公司任何職務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.